• There are no suggestions because the search field is empty.

Ward Neefs

AI & Digitalization Expert

Ward Neefs is a life-science professional with a strong focus on software, data, and digitization in the pharmaceutical sector. At QbD Group, he applies his background in bio-engineering and artificial intelligence to optimize digital systems and processes for pharma manufacturing.

Biography

Ward Neefs holds a master's degree in bio-engineering (bio-nanotechnology) and a second master’s in Artificial Intelligence, both obtained at KU Leuven University. His fascination with software and data in life sciences was born during his studies and has continued to shape his professional journey.

Since joining QbD Group, Ward has contributed to key digital transformation projects. He worked on Master Batch Record implementations for COVID vaccine production at Pfizer and later acted as a business analyst for the rollout of a new Manufacturing Execution System (MES) at Pfizer Puurs.

Currently, Ward is supporting a manufacturing-focused project at Sanofi, where he contributes to process automation and code flexibility improvements.

Ward regularly shares insights on the role of AI in pharma and has contributed to QbD’s blog. He also participated in two panel discussions on AI in medical writing at the EMWA 2024 Spring Conference in Valencia.

AI-and-machine-learning-validati

Ward's key areas of expertise

Artificial Intelligence in Pharma

Applying AI to improve pharmaceutical processes, systems, and decision-making. 

MES & Batch Record Implementation

Digitalizing manufacturing operations through structured data and automation. 

Process Automation

Improving process flexibility and software code logic in GMP-regulated environments.

Digital Health & Data Strategy

Combining engineering expertise with AI to support digital health innovations.

quote-image

AI is here to stay. Yes, AI is a hype — but for good reason, and it will no doubt change society (it already has). However, there is a profound lack of understanding of how it actually works among most users. This carries some risk: it can lead to overestimating its capabilities, or to misuse due to a lack of understanding. It can also create a culture of fear, as humans tend to fear what they do not understand. It is therefore important that, moving forward, we aim to demystify AI model architectures and move away from this extreme black-box view of AI.

Ward Neefs

Circles_quote

Explore our expert content

preview_image
Blog

MDSW for Startups: A Practical Guide to Compliant Medical Software Development

Medical Device Software (MDSW) development can feel like a regulatory...
preview_image
Blog

Life Sciences Digitization: Your Compliance Roadmap

In the ever‑evolving life sciences industry, digitization is no longer...
preview_image
Blog

MDR & Cybersecurity: What Your Technical File Needs to Prove

Cybersecurity has become a fundamental requirement under the Medical Device...
preview_image
Blog

Eudralex Annex 11 Revision: What Pharma Companies Need to Know Before 2026

The European Commission is revising Annex 11 of the EU GMP guidelines, and...
preview_image
Blog

Validating Your LIMS: A Strategic Guide to Compliance and Confidence

A Laboratory Information Management System (LIMS) is more than just...
overlay
Webinar - ATMP Supply Chain Navigating the Challenges and Exploring the Vein-to-Vein Strategy - QbD Group (2)

Don't miss the latest updates in life sciences

Circles_banner_short-1